Business Description
Jazz Pharmaceuticals PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B4Q5ZN47
Compare
Compare
Traded in other countries / regions
JAZZ.USAJ7Z.Germany1JAZZ.ItalyJAZZ.Mexico Index Membership
Russell 1000Russell 3000 IPO Date
2007-06-01Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.48 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 1.3 | |||||
| Debt-to-EBITDA | 4.34 | |||||
| Interest Coverage | 2.63 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.49 | |||||
| Beneish M-Score | -3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.9 | |||||
| 3-Year EBITDA Growth Rate | 19.9 | |||||
| 3-Year EPS without NRI Growth Rate | 8.8 | |||||
| 3-Year FCF Growth Rate | 18.5 | |||||
| 3-Year Book Growth Rate | 1.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.16 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.3 | |||||
| 9-Day RSI | 55.9 | |||||
| 14-Day RSI | 52.31 | |||||
| 3-1 Month Momentum % | -13.54 | |||||
| 6-1 Month Momentum % | -12.25 | |||||
| 12-1 Month Momentum % | 1.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.38 | |||||
| Quick Ratio | 2.97 | |||||
| Cash Ratio | 2.1 | |||||
| Days Inventory | 422.48 | |||||
| Days Sales Outstanding | 62.83 | |||||
| Days Payable | 70.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | -1.53 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.81 | |||||
| Operating Margin % | 14.63 | |||||
| Net Margin % | 11.86 | |||||
| EBITDA Margin % | 30.74 | |||||
| FCF Margin % | 36.62 | |||||
| ROE % | 12.12 | |||||
| ROA % | 4.12 | |||||
| ROIC % | 9.39 | |||||
| 3-Year ROIIC % | -12.71 | |||||
| ROC (Joel Greenblatt) % | 64.69 | |||||
| ROCE % | 5.64 | |||||
| Years of Profitability over Past 10-Year | 8 | |||||
| Moat score | 5 | |||||
| Tariff score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.66 | |||||
| Forward PE Ratio | 22.19 | |||||
| PE Ratio without NRI | 5.44 | |||||
| Shiller PE Ratio | 21.43 | |||||
| Price-to-Owner-Earnings | 7.03 | |||||
| PEG Ratio | 0.81 | |||||
| PS Ratio | 1.72 | |||||
| PB Ratio | 1.62 | |||||
| Price-to-Free-Cash-Flow | 4.69 | |||||
| Price-to-Operating-Cash-Flow | 4.46 | |||||
| EV-to-EBIT | 16.11 | |||||
| EV-to-Forward-EBIT | 43.82 | |||||
| EV-to-EBITDA | 7.58 | |||||
| EV-to-Forward-EBITDA | 16.8 | |||||
| EV-to-Revenue | 2.33 | |||||
| EV-to-Forward-Revenue | 2.19 | |||||
| EV-to-FCF | 6.36 | |||||
| Price-to-GF-Value | 0.74 | |||||
| Price-to-Projected-FCF | 0.51 | |||||
| Price-to-DCF (Earnings Based) | 0.32 | |||||
| Price-to-DCF (FCF Based) | 0.18 | |||||
| Price-to-Median-PS-Value | 0.44 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.54 | |||||
| Earnings Yield (Greenblatt) % | 6.21 | |||||
| FCF Yield % | 22.38 | |||||
| Forward Rate of Return (Yacktman) % | 23.21 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers